[Treatment of cancer of the kidney with interleukin 2 in adults, the Lyon experience].
Like interferon-alpha, interleukin 2 (IL2) is active on metastatic kidney cancers, which are regarded as chemoresistant tumors. Out of 20 to 30% objective responses, 5 to 10% complete remissions are reported with various IL2 delivery schedules. The considerable toxicity is well mastered at present, thus allowing treatment in non-intensive care departments, or even in an ambulatory mode for subcutaneous administration. Even though Interleukin 2 has been authorized for sale in France, optimal mode of administration, the role of the IL2-interferon-alpha combination or the predictive factors of response to treatment still raise many questions.
Negrier
S
S
Département de Médecine Carcinologique, Centre Léon Bérard, Lyon.
Mercatello
A
A
Coronel
B
B
Ravaud
A
A
Merrouche
Y
Y
Bret
M
M
Lanier
F
F
Moskovtchenko
J F
JF
Philip
T
T
D004359:Drug Therapy, Combination; D005602:France; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000401:mortality / Q000556:secondary / Q000628:therapy*
D016898:Interferon-alpha; D007376:Interleukin-2
Traitement par l'interleukine 2 du cancer du rein de l'adulte, l'expérience lyonnaise.